358,036 Shares in RxSight, Inc. $RXST Acquired by Walleye Capital LLC

Walleye Capital LLC bought a new position in shares of RxSight, Inc. (NASDAQ:RXST) during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 358,036 shares of the company’s stock, valued at approximately $1,726,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in RXST. Healthcare of Ontario Pension Plan Trust Fund raised its stake in shares of RxSight by 761.0% in the first quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 1,131,400 shares of the company’s stock valued at $6,969,000 after acquiring an additional 1,000,000 shares in the last quarter. Public Employees Retirement System of Ohio acquired a new position in RxSight during the 1st quarter worth $81,000. Hsbc Holdings PLC acquired a new position in RxSight during the 1st quarter worth $473,000. ADAR1 Capital Management LLC increased its holdings in RxSight by 98.4% during the 1st quarter. ADAR1 Capital Management LLC now owns 43,250 shares of the company’s stock worth $266,000 after purchasing an additional 21,447 shares during the period. Finally, Summit Securities Group LLC purchased a new stake in RxSight during the 1st quarter worth about $30,000. Hedge funds and other institutional investors own 78.78% of the company’s stock.

RxSight Price Performance

NASDAQ:RXST opened at $6.89 on Friday. The firm has a market capitalization of $286.56 million, a PE ratio of -6.10 and a beta of 1.13. The business’s fifty day moving average price is $5.50 and its 200 day moving average price is $6.55. RxSight, Inc. has a 12 month low of $4.48 and a 12 month high of $13.22.

RxSight (NASDAQ:RXST) last posted its quarterly earnings results on Wednesday, August 5th. The company reported ($0.29) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.04. The company had revenue of $33.74 million for the quarter, compared to analysts’ expectations of $32.55 million. RxSight had a negative return on equity of 17.35% and a negative net margin of 36.80%. As a group, equities analysts anticipate that RxSight, Inc. will post -1.31 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the company. Stifel Nicolaus reduced their price target on RxSight from $8.00 to $7.00 and set a “hold” rating on the stock in a research report on Monday, August 10th. UBS Group boosted their price objective on RxSight from $5.50 to $6.30 and gave the stock a “neutral” rating in a research report on Thursday, August 6th. Wells Fargo & Company cut their target price on shares of RxSight from $11.00 to $9.00 and set an “equal weight” rating on the stock in a research note on Thursday, May 7th. Needham & Company LLC reaffirmed a “buy” rating and issued a $11.00 target price on shares of RxSight in a report on Tuesday, July 7th. Finally, Bank of America decreased their price target on shares of RxSight from $8.00 to $6.50 and set an “underperform” rating for the company in a research note on Tuesday, July 7th. Two analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and three have issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Reduce” and an average price target of $8.37.

About RxSight

RxSight, Inc is a medical technology company focused on the development and commercialization of advanced intraocular lens (IOL) systems for patients undergoing cataract surgery and lens replacement procedures. The company’s flagship product, the Light Adjustable Lens (LAL), is designed to provide customized vision correction by allowing non‐invasive post‐operative adjustments. Using ultraviolet light, surgeons can fine‐tune the lens power after implantation to achieve optimal visual outcomes, reducing reliance on glasses or contact lenses and enhancing patient satisfaction.

Founded in 2011 and headquartered in Aliso Viejo, California, RxSight has pursued regulatory clearances and market access across multiple regions.